The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Discussion of the results from the BEAT-meso trial in pleural mesothelioma
Dean Fennell, FRCP, PhD, University of Leicester, Leicester, UK, discusses results from the Phase III BEAT-meso trial (NCT03762018) of atezolizumab with bevacizumab and standard chemotherapy as a first-line treatment for advanced pleural mesothelioma (PM). An increase in median progression free survival (PFS) was seen with atezolizumab and whilst this did not translate into a significant increase in overall survival (OS), it did push the median OS to over 20 months, which has not been achieved in previous trials on advanced PM. Additionally, atezolizumab was very effective in non-epithelioid cases. This study reflects the promising movement towards combination of chemotherapy and immunotherapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Bristol Myers Squibb; RS Oncology (Inst)
Consulting or Advisory Role – Bristol-Myers Squibb; RS Oncology
Speakers’ Bureau – BMS; Boehringer Ingelheim
Research Funding – Astex Pharmaceuticals (Inst); Bayer (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Owkin (Inst); Roche UK (Inst); RS Oncology (Inst)
Travel, Accommodations, Expenses – Bristol-Myers Squibb; Janssen Oncology; RS Oncology
